- Case Report
- Open Access
Two cases of breast carcinoma with osteoclastic giant cells: Are the osteoclastic giant cells pro-tumoural differentiation of macrophages?
© Shishido-Hara et al; licensee BioMed Central Ltd. 2010
Received: 10 April 2010
Accepted: 23 August 2010
Published: 23 August 2010
Breast carcinoma with osteoclastic giant cells (OGCs) is characterized by multinucleated OGCs, and usually displays inflammatory hypervascular stroma. OGCs may derive from tumor-associated macrophages, but their nature remains controversial. We report two cases, in which OGCs appear in common microenvironment despite different tumoural histology. A 44-year-old woman (Case 1) had OGCs accompanying invasive ductal carcinoma, and an 83-year-old woman (Case 2) with carcinosarcoma. Immunohistochemically, in both cases, tumoural and non-tumoural cells strongly expressed VEGF and MMP12, which promote macrophage migration and angiogenesis. The Chalkley count on CD-31-stained sections revealed elevated angiogenesis in both cases. The OGCs expressed bone-osteoclast markers (MMP9, TRAP, cathepsin K) and a histiocyte marker (CD68), but not an MHC class II antigen, HLA-DR. The results indicate a pathogenesis: regardless of tumoural histology, OGCs derive from macrophages, likely in response to hypervascular microenvironments with secretion of common cytokines. The OGCs have acquired bone-osteoclast-like characteristics, but lost antigen presentation abilities as an anti-cancer defense. Appearance of OGCs may not be anti-tumoural immunological reactions, but rather pro-tumoural differentiation of macrophage responding to hypervascular microenvironments induced by breast cancer.
Breast carcinoma with osteoclastic giant cells is a rare entity that falls under the WHO classification of invasive ductal carcinoma, not otherwise specified . This tumor is characterized by the presence of osteoclastic giant cells (OGCs), the nature of which remains controversial. OGCs accompany a variety of breast tumors, including invasive ductal carcinoma and cribriform, tubular, mucinous, papillary, lobular, squamous, and other metaplastic patterns. Despite divergent tumor histology, most cases present a well-demarcated mass with characteristic inflammatory and hypervascular stroma .
OGCs are agreed to be of histiocytic origin, and are hypothesized to derive from macrophages . Macrophages display marked plasticity with both pro-tumoural and anti-tumoural activities [4–6]. Their classical anti-tumoural roles include promotion of specific immunity by inducing T cell activation via antigen presentation. Recent studies have also focused on their direct or indirect pro-tumoural functions: enhancement of angiogenesis and cancer cell growth and spread [4, 6]. Macrophages secrete growth factors such as epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF), and produce proteases including matrix metalloproteinases (MMPs). Both VEGF and MMP12 enhance macrophage migration [7, 8], and VEGF also regulates angiogenesis and lymphangiogenesis through different types of receptors. Microenvironments, with secretion of cytokines, seem to affect progression of breast cancer [9, 10], and may also determine whether OGCs are formed. However, in current thinking, the prognosis of breast carcinoma with OGCs is considered to be related to the tumoural histology, and not influenced by the presence of OGCs .
Here, we report two cases of breast carcinoma with OGCs associated with invasive ductal carcinoma (Case 1) or carcinosarcoma (Case 2). Despite different tumoural histology, two cases displayed common microenvironments with expression of VEGF and MMP12, suggesting enhanced macrophage migration and angiogenesis. The OGCs presented phenotypic resemblance to the osteoclasts in the bone, and lacked antigen presentation abilities. Macrophage plasticity responding microenvironments is discussed, in relation to prognosis of breast carcinoma.
Case 1: A 44-year-old woman presented with a lump in the lower inner quadrant of her right breast. Physical examination revealed a well-demarcated firm tumor with good mobility. Mammography and ultrasonography revealed a well-circumscribed tumor of 30 × 20 × 25 mm, and magnetic resonance imaging (MRI) showed rich vascularity, especially in the periphery. Fine-needle aspiration and core needle biopsy demonstrated invasive ductal carcinoma with multi-nucleated OGCs. Partial mastectomy was performed following sentinel lymph node biopsy. There was no metastasis to the sentinel lymph nodes, and the postoperative stage was pT2 N0 M0, stage IIA.
Case 2: An 83-year-old woman presented with a painful lump in the upper inner quadrant of her right breast. Ultrasonography revealed a well-defined mass of 19 × 16 × 10 mm. Both mammography and MRI suggested malignancy. As the specimen of aspiration cytology did not contain enough epithelial cells for diagnosis, an intraoperative frozen section was examined, leading to diagnosis of malignant tumor. Partial mastectomy was performed, and the final pathologic diagnosis was beast carcinoma with OGCs. The postoperative stage for this patient was also pT2 N0 M0, stage IIA.
Materials and methods
For histological analysis, the surgical specimens were fixed in 10% buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. For immunohistochemical analysis, the sections were deparafinized and reacted with primary antibodies, followed by the immunoperoxidase method with a commercial kit (DakoCytomation Co Ltd, Glostrup, Denmark). The primary antibodies used in this study are as follows: ER (1D5, 1:100, Dako), PgR (PgR636, 1:400, Dako), HER2 (polyclonal, 1:1, Dako), CKAE1/AE3 (AE1/AE3, 1:100, Dako), Vimentin (V9, 1:2, Nichirei), VEGF (A-20, 1:400, Santacruz), MMP9 (polyclonal, 1:5000, Abcam), MMP12 (polyclonal, 1:100, Abcam), CD31 (JC70A, 1:50, Dako), CD68 (PGM-1, 1:100, Dako), HLA-DR (TAL1B5, 1:100, Dako), TRAP (26E5, 1:100, Novocastra), Cathepsin K (182-12G5, 1:10000, Dai-ichi fain chemical).
Gross and microscopic findings
The tumor in Case 2 also showed a well-circumscribed gross appearance, measuring 2.2 × 1.5 cm on the maximum cut plane. The tumor was rather whitish, but contained a small (5 mm) hemorrhagic area (Figure 1I). Microscopically, the main part of tumor consisted of spindle-shaped sarcomatous cells with frequent mitotic figures, and there were also foci of ductal carcinoma cells with an intraductal component (Figure 1J-L). Inflammatory cells and multinucleated OGCs were seen in the hypervascular stroma (Figure 1M, N). Immunohistochemically, the ductal carcinoma cells were positive for CK AE1/AE3 (Figure 1O) but not ER, PgR, or HER2. The spindle-shaped tumor cells constituting most of the tumor were not reactive for CK AE1/AE3, but instead were strongly positive for vimentin (Figure 1P). Thus, the case was diagnosed as breast carcinoma with OGCs, and the tumor was equivalent to metaplastic carcinoma with mesenchymal component, corresponding to so-called carcinosarcoma.
Topography of CD68-positive cells and expression of chemotactic agents
To assess the microenvironment of the tumors, we examined the expression of two chemoattractants for macrophage migration and angiogenesis, VEGF and MMP12. Prominent expression of VEGF and MMP12 was observed in most tumor cells, most inflammatory cells, and even neighboring normal mammary glands both in Case 1 and Case 2 (Figure 2G-R). The OGCs, in both cases, also displayed marked expression of VEGF and MMP12.
Statistic evaluation of microvessel density
In hypervascular stroma of both cases, microvessel density was evaluated according to the Chalkley count on CD-31-stained sections, as described earlier. The mean values of the three most vascular areas (hot spot) were 9.6 for Case 1 and 10.7 for Case 2, respectively. These counts were much higher than the average Chalkley count of a total 330 invasive breast carcinoma cases, 5.75 (range 2.33 - 10.67, median 5.67, SD 1.54), reported in a previous study[11, 12].
Phenotype of the OGCs in the breast
In this study, we demonstrated that the OGCs appear in relation to inflammatory hypervascular stroma around breast carcinoma regardless of histology. Abundant VEGF and MMP12 were secreted from both tumoural and non-tumoural cells, and these cytokines promote macrophage migration and angiogenesis. Notable increase of microvessel density was actually shown by the Chalkley count in inflammatory stroma of both cases. The OGCs are likely generated by syncytial fusion of macrophages, but not by mitosis without cell division. Thus, bi-, tri-, or oligo-nuclear CD-68 positive cells were scattered around OGCs, but nuclear mitotic figures were not observed. Phenotypic resemblance of OGCs to the osteoclasts in the bone was confirmed with expression of MMP9, TRAP, and cathepsin K. The OGCs were negative for HLA-DR, and lacked antigen presentation abilities as anti-cancer defence.
Macrophages are multifunctional, showing marked phenotypic plasticity in response to microenvironments. Indeed, tumor-associated macrophages (TAMs) isolated from breast cancer in vitro differentiated into multinucleated giant cells with bone resorption . A characteristic inflammatory and hypervascular stroma is commonly observed in breast carcinoma with OGCs, regardless of histology of tumoural cells. This characteristic stroma may indicate secretion of specific cytokines, and we, in this study, first demonstrated marked expression of VEGF and MMP12. Therefore, appearance of OGCs may not be anti-tumoural immunological reactions, but rather pro-tumoural differentiation of macrophage responding to hypervascular microenvironments induced by breast cancer. However, the further case series study is necessary to elucidate the prognostic or biological significance of OGCs in association with breast carcinoma.
In the bone tissue, osteoclast differentiation seems tightly associated with signaling related to RANKL (receptor activator of nuclear factor-κB ligand) , or VEGF and its receptor Flt-1 . Flt-1, expressed on human monocyte/macrophage lineage cells , also regulates macrophage migration in response to VEGF . To test for such differentiation signaling in the OGCs in the breast, we also examined expression of RANKL and Flt-1. Weak but distinct expression of Flt-1 was detected in the OGCs of both Case 1 and Case 2, but expression of RANKL was not clear (data not shown). Thus, it is still uncertain if osteoclast differentiation signaling function in the breast, mimicking in the bone.
The OGCs likely develop from macrophages in response to pro-tumoural microenvironment defied by cytokines, favoring macrophage migration and angiogenesis. The OGCs have acquired bone-osteoclast-like characteristics, but no more have antigen presentation abilities as anti-cancer defence. Macrophages and angiogenesis may imply the poor prognosis of the breast cancer [16, 17]. Therefore, the appearance of OGCs is not merely histiocytic reactions, but better taken as a part of pathology of breast tumours.
Written informed consent was obtained from both patients for publication of this case report and any accompanying images.
The authors thank Kaoruko Kojima and Natsuko Mizutani for assistance and comments. This work is supported, in part, by Health and Labour Sciences Research Grants and Japanese Grant-in-Aid for Scientific Research.
- Fattaneh A, Tavassolo B, Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumor of the breast and female genital organs. 2003, Lyon, IARC PressGoogle Scholar
- Agnanits NT, Rosen PP: Rosen's breast pathology. 2001, Philadelphia, Lippincot Williams & WilkinsGoogle Scholar
- Quinn JM, McGee JO, Athanasou NA: Human tumour-associated macrophages differentiate into osteoclastic bone-resorbing cells. J Pathol. 1998, 184: 31-36. 10.1002/(SICI)1096-9896(199801)184:1<31::AID-PATH962>3.0.CO;2-V.View ArticlePubMedGoogle Scholar
- Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66: 605-612. 10.1158/0008-5472.CAN-05-4005.View ArticlePubMedGoogle Scholar
- Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008, 8: 958-969. 10.1038/nri2448.PubMed CentralView ArticlePubMedGoogle Scholar
- Siveen KS, Kuttan G: Role of macrophages in tumour progression. Immunol Lett. 2009, 123: 97-102. 10.1016/j.imlet.2009.02.011.View ArticlePubMedGoogle Scholar
- Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996, 87: 3336-3343.PubMedGoogle Scholar
- Nenan S, Boichot E, Lagente V, Bertrand CP: Macrophage elastase (MMP-12): a pro-inflammatory mediator?. Mem Inst Oswaldo Cruz. 2005, 100 (Suppl 1): 167-172.View ArticlePubMedGoogle Scholar
- Pollard JW: Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008, 84: 623-630. 10.1189/jlb.1107762.PubMed CentralView ArticlePubMedGoogle Scholar
- Yu JL, Rak JW: Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res. 2003, 5: 83-88. 10.1186/bcr573.PubMed CentralView ArticlePubMedGoogle Scholar
- Dhakal HP, Bassarova A, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, Wiedswang G, Giercksky KE, Nesland JM: Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count. J Pathol. 1998, 184: 31-36. 10.1002/(SICI)1096-9896(199801)184:1<31::AID-PATH962>3.0.CO;2-V.View ArticleGoogle Scholar
- Hansen S, Sørensen FB, Vach W, Grabau DA, Bak M, Rose C: Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients. Histopathology. 2004, 44: 428-36. 10.1111/j.1365-2559.2004.01848.x.View ArticlePubMedGoogle Scholar
- Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature. 2003, 423: 337-342. 10.1038/nature01658.View ArticlePubMedGoogle Scholar
- Aldridge SE, Lennard TW, Williams JR, Birch MA: Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem Biophys Res Commun. 2005, 335: 793-798. 10.1016/j.bbrc.2005.07.145.View ArticlePubMedGoogle Scholar
- Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M: Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood. 2001, 97: 785-791. 10.1182/blood.V97.3.785.View ArticlePubMedGoogle Scholar
- Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL: Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol. 2000, 190: 430-436. 10.1002/(SICI)1096-9896(200003)190:4<430::AID-PATH538>3.0.CO;2-6.View ArticlePubMedGoogle Scholar
- Leek RD, Harris AL: Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002, 7: 177-189. 10.1023/A:1020304003704.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.